Home > Insider Trading > Filing (0001209191-14-060551)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1157602	Vitae Pharmaceuticals Inc	VTAE	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1239242	E Bryan Roberts	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-09-29	48,333	$0.00	48,333	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	214,820	$0.00	214,820	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	5,367	$0.00	5,367	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	227,117	$0.00	275,450	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	1,009,414	$0.00	1,224,234	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	25,233	$0.00	30,600	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	9,285	$0.00	284,735	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	41,270	$0.00	1,265,504	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	1,031	$0.00	31,631	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	139,019	$8.00	423,754	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	617,868	$8.00	1,883,372	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2014-09-29	15,446	$8.00	47,077	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-2 Preferred Stock	Disposition	2014-09-29	32,086	$0.00	48,333	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2014-09-29	142,607	$0.00	214,820	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2014-09-29	3,563	$0.00	5,367	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-09-29	227,117	$0.00	227,117	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-09-29	1,009,414	$0.00	1,009,414	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-09-29	25,233	$0.00	25,233	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-09-29	9,285	$0.00	9,285	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-09-29	41,270	$0.00	41,270	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-09-29	1,031	$0.00	1,031	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each outstanding share of Series A-2 Preferred Stock automatically converted on a 1:1.50638118 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.
The reportable securities are owned by Venrock Associates ("VA"). Dr. Roberts is a general partner of VA and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in them.
The reportable securities are owned by Venrock Associates III, L.P. ("VA III"). The sole general partner of VA III is Venrock Management III, LLC ("VM III") and it may be deemed to own these shares. Dr. Roberts is a member of VM III and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in them.
The reportable securities are owned by Venrock Entrepreneurs Fund III, L.P. ("VEF III"). The sole general partner of VEF III is VEF Management III, LLC ("VEFM III") and it may be deemed to own these shares. Dr. Roberts is a member of VEFM III and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in them.
Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted on a 1:1 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.